(Q46430969)

English

Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients

scientific article published on 18 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Yvonne Nadine Fahmueller

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

Dorothea Nagel

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

Ralf-Thorsten Hoffmann

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

Klaus Tatsch

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

Tobias Jakobs

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

Petra Stieber

6

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

Stefan Holdenrieder

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

language of work or name

0 references

publication date

18 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

132

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

10

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

2349-2358

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Treatment of liver metastases, an update on the possibilities and results

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Radiofrequency ablation of unresectable hepatic malignancies: lessons learned

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Radioembolization of liver tumors with yttrium-90 microspheres

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Partial irradiation of the liver.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Clinical care and technical recommendations for 90yttrium microsphere treatment of liver cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Tumour-to-normal uptake ratio of 90Y microspheres in hepatic cancer assessed with 99Tcm macroaggregated albumin

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease-Is it feasible?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Nucleosomes in pancreatic cancer patients during radiochemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Apoptotic DNA fragmentation and tissue homeostasis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

HMGB1 and RAGE in inflammation and cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

HMGB1 loves company

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Immunogenic cell death modalities and their impact on cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Immunological aspects of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

High-mobility group box 1 and cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Assessing tumor response to therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27894

21 January 2018

Identifiers

10.1002/IJC.27894

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

release_3wf2mxfcr5gtzggwyxxynmmnqu

1 reference

https://api.fatcat.wiki/v0/release/3wf2mxfcr5gtzggwyxxynmmnqu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23047645

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46430969&oldid=2111158327"